Will Invitae Ever Turn a Profit?
Genetic-testing leader Invitae (NYSE: NVTA) has promised to usher in a new age of healthcare, one influenced by every individual's unique genetic profile. To do so, it's ditching the industry's old business model that relied on selling low volumes of really expensive tests in favor of one that relies on selling high volumes of affordable tests. Accessibility over propriety.
The strategy appears to be working. Year-over-year revenue growth of 189% in the third quarter of 2017 certainly shows the business is on the right trajectory.
That means investors can turn their attention to the next unanswered question: When will the high-growth strategy result in positive numbers on the bottom line? Will Invitae ever turn a profit?
Source: Fool.com
